



Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference

May 26, 2021

BOSTON--(BUSINESS WIRE)--May 26, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that management will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:00 p.m. ET.

The fireside chat will be webcast live and can be accessed by visiting the Investors & Media section of the company's website at www.ikenaoncology.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Ikena Oncology

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs. To learn more visit www.ikenaoncology.com or follow us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210526005321/en/): <https://www.businesswire.com/news/home/20210526005321/en/>

Media Contact:

Liza Sullivan
Argot Partners
617-340-6073
liza@argotpartners.com

Investor Contact:

Sam Martin
Argot Partners
646-233-4302
sam@argotpartners.com

Source: Ikena Oncology, Inc.